201 related articles for article (PubMed ID: 37728696)
1. VEIN STEP: A Prospective, Observational, International Study to Assess Effectiveness of Conservative Treatments in Chronic Venous Disease.
Mezalek ZT; Feodor T; Chernukha L; Chen Z; Rueda A; Sánchez IE; Ochoa AJG; Chirol J; Blanc-Guillemaud V; Lohier-Durel C; Ulloa JH
Adv Ther; 2023 Nov; 40(11):5016-5036. PubMed ID: 37728696
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
Kakkos SK; Nicolaides AN
Int Angiol; 2018 Apr; 37(2):143-154. PubMed ID: 29385792
[TBL] [Abstract][Full Text] [Related]
3. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.
Jantet G
Angiology; 2002; 53(3):245-56. PubMed ID: 12025911
[TBL] [Abstract][Full Text] [Related]
4. Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting.
Bogachev V; Boldin B; Turkin P; Samenkov A; Dzhenina O
Future Cardiol; 2022 Sep; 18(10):777-785. PubMed ID: 36004765
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs.
Gianesini S; De Luca L; Feodor T; Taha W; Bozkurt K; Lurie F
Adv Ther; 2023 Dec; 40(12):5137-5154. PubMed ID: 37768506
[TBL] [Abstract][Full Text] [Related]
6. Administration of Micronized Purified Flavonoid Fraction During Sclerotherapy of Reticular Veins and Telangiectasias: Results of the National, Multicenter, Observational Program VEIN ACT PROLONGED-C1.
Bogachev VY; Boldin BV; Turkin PY
Adv Ther; 2018 Jul; 35(7):1001-1008. PubMed ID: 29949043
[TBL] [Abstract][Full Text] [Related]
7. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids.
Jantet G
Angiology; 2000 Jan; 51(1):31-7. PubMed ID: 10667641
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of micronized purified flavonoid fraction in treatment of chronic venous oedema].
Bogachev VI; Boldin BV; Turkin PI; Samenkov AI
Angiol Sosud Khir; 2020; 26(2):86-94. PubMed ID: 32597888
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of MPFF 1000 mg oral suspension on CVD C0s-C1-related symptoms and quality of life.
Maggioli A; Carpentier P
Int Angiol; 2019 Apr; 38(2):83-89. PubMed ID: 31056892
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial.
Carpentier P; van Bellen B; Karetova D; Hanafiah H; Enriquez-Vega E; Kirienko A; Dzupina A; Sabovic M; Reina Gutierrez L; Subwongcharoen S; Tüzün H; Maggioli A
Int Angiol; 2017 Oct; 36(5):402-409. PubMed ID: 28206732
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial.
Rabe E; Agus GB; Roztocil K
Int Angiol; 2015 Oct; 34(5):428-36. PubMed ID: 25972136
[TBL] [Abstract][Full Text] [Related]
12. Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New Evidence.
Ulloa JH
Adv Ther; 2019 Mar; 36(Suppl 1):20-25. PubMed ID: 30758743
[TBL] [Abstract][Full Text] [Related]
13. Systematic literature review and expert meeting report on health-related quality of life in chronic venous disease.
Ulloa JH; Lurie F; Santiago FR; Gianesini S; Reina L; Wang J; Jindal R; Taha W; Bokuchava M; Mansilha A
Int Angiol; 2023 Dec; 42(6):465-476. PubMed ID: 38015554
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of once-daily micronized purified flavonoid fraction 1000 mg tablet in patients with symptomatic chronic venous disease.
Kirienko A; Radak D; Maggioli A
Curr Med Res Opin; 2019 Mar; 35(3):553-557. PubMed ID: 29992831
[TBL] [Abstract][Full Text] [Related]
15. [Comparative efficacy of various methods of treatment of chronic venous oedema in real clinical practice].
Bogachev VI; Boldin BV; Turkin PI; Samenkov AI;
Angiol Sosud Khir; 2021; 27(3):77-83. PubMed ID: 34528591
[TBL] [Abstract][Full Text] [Related]
16. Daflon 500 mg: symptoms and edema clinical update.
Ramelet AA
Angiology; 2005; 56 Suppl 1():S25-32. PubMed ID: 16193223
[TBL] [Abstract][Full Text] [Related]
17. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease.
Nicolaides AN
Adv Ther; 2020 Feb; 37(Suppl 1):1-5. PubMed ID: 31970659
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy of Conservative Treatment with Micronized Purified Flavonoid Fraction in Female Patients with Pelvic Congestion Syndrome.
Akhmetzianov RV; Bredikhin RA
Pain Ther; 2021 Dec; 10(2):1567-1578. PubMed ID: 34537951
[TBL] [Abstract][Full Text] [Related]
19. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence.
Cazaubon M; Benigni JP; Steinbruch M; Jabbour V; Gouhier-Kodas C
Vasc Health Risk Manag; 2021; 17():591-600. PubMed ID: 34556990
[TBL] [Abstract][Full Text] [Related]
20. New Perspectives on Micronised Purified Flavonoid Fraction in Chronic Venous Disease: From Microvalves to Clinical Effectiveness.
Bouskela E; Lugli M; Nicolaides A
Adv Ther; 2022 Oct; 39(10):4413-4422. PubMed ID: 35951224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
